Llamas-Velasco M, Castañeda S, Sánchez-Pérez J, Vicente-Rabaneda EF, Pardo J, Cabeza-Martínez R, Miranda Fontes M, Márquez J, Calvo-Alén J, Armesto S, Belinchón I, Gómez A, Miranda MD, Martínez Pardo S, Merino L, Casado MA, Amaro A, Ordovás M, Yébenes M, Casado A
Cost of illness in patients with psoriasis and psoriatic arthritis disease. COEPSO Study
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Roncero C, Dorado ML, Orengo T, Ortega RL, Palma-Álvarez RF, Muñoz A, Casado MA, Grau-López L, Ahuir J
Direct healthcare costs for the management of patients with opioid use disorder treated with methadone and buprenorphine/naloxone in real-world setting in Spain. Costedopia study
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
García A, Domínguez-Hernández R, Casado MA
Economic evaluation of an electronic health record alert by age in primary care for the detection of patients with chronic hepatitis C
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Taxonera C, de Andrés-Nogales F, García S, Sánchez-Guerrero A, Menchen B, Peral C, Cábez A, Gómez S, López A, Casado MÁ, Menchén L
Cost-effectiveness of Tofacitinib for the Treatment of Moderate-to-severe Ulcerative Colitis After Conventional Therapy in Spain
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
de Andrés-Nogales F, Gay-Pobes PR, Inês M, Polanco Sánchez C, Alves D, Oyagüez I
Cost-effectiveness analysis of apixaban versus edoxaban for stroke prevention in non-valvular atrial fibrilation Portuguese patients
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Menchén L, de Andrés-Nogales F, García S, Sánchez-Guerrero A, Menchen B, Cábez A, Gómez S, López A, Casado MÁ, Peral C, Taxonera C
Cost-effectivenes of Tofacitinib for the Treatment of Moderate-to-severe Ulcerative Colitis After Biologic Failure or Intolerance in Spain
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
de Andrés-Nogales F, Casado MÁ, Zarranz-Ventura J, Udaondo P, Trillo JL, Ruiz-Moreno JM, Rodriguez-Maqueda M, Poveda JL, Peralta G, Ortiz P, Martínez-Sesmero JM, Martínez-Olmos J, Ignacio E, García-Layana A, Álvarez E, Zulueta J, Mur C, Martínez M
Extended Multicriteria Decision Analysis in Diabetic Macular Edema. MULTIDEX-EMD Extension Study
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
de Andrés-Nogales F, Ruiz-Moreno JM, Oyagüez I, Casado MA
Extended loading dose of anti-VEGF treatment in diabetic macular edema patients: A cost-consequence analysis
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Presa M, Varela C, Oyagüez I
Costs of cytokine release syndrome (CRS) and neurological events (NE) in patients with relapsed/refractory non-hodgkin lymphoma receiving lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 clinical trial: a micro-costing study from the Spanish National Health System (NHS) perspective
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Presa M, Soria A, Oyagüez I, Espinosa E, Echave M, Berrocal A, Manzano JL, Suarez J, Polanco C